Cargando…

The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy

Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regu...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Tao, Yin, Huanhuan, Lu, Yanting, Liu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063801/
https://www.ncbi.nlm.nih.gov/pubmed/35517982
http://dx.doi.org/10.2147/DDDT.S355059
_version_ 1784699239170834432
author An, Tao
Yin, Huanhuan
Lu, Yanting
Liu, Feng
author_facet An, Tao
Yin, Huanhuan
Lu, Yanting
Liu, Feng
author_sort An, Tao
collection PubMed
description Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regulators in carcinogenesis. Notably, PTL was also the first small molecule reported to eradicate cancer stem cells. Nevertheless, the clinical application of PTL as an antitumor agent remains limited, owing to some disadvantages such as low water solubility and poor bioavailability. Thus, nanomedicine has attracted much interest because of its great potential for transporting poorly soluble drugs to desired body sites. In view of the significant advantages over their free small-molecule counterparts, nanoparticle delivery systems appear to be a potential solution for addressing the delivery of hydrophobic drugs, including PTL. In this review, we summarized the key anticancer mechanisms underlined by PTL as well as engineered PTL nanoparticles synthesized to date. Therefore, PTL nanoformulations could be an alternative strategy to maximize the therapeutic value of PTL.
format Online
Article
Text
id pubmed-9063801
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90638012022-05-04 The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy An, Tao Yin, Huanhuan Lu, Yanting Liu, Feng Drug Des Devel Ther Review Plant-derived sesquiterpene lactones are promising natural sources for the discovery of anti-cancer drugs. As an extensively studied sesquiterpene lactone, the tumor suppression effect of parthenolide (PTL) has been clarified by targeting a number of prominent signaling pathways and key protein regulators in carcinogenesis. Notably, PTL was also the first small molecule reported to eradicate cancer stem cells. Nevertheless, the clinical application of PTL as an antitumor agent remains limited, owing to some disadvantages such as low water solubility and poor bioavailability. Thus, nanomedicine has attracted much interest because of its great potential for transporting poorly soluble drugs to desired body sites. In view of the significant advantages over their free small-molecule counterparts, nanoparticle delivery systems appear to be a potential solution for addressing the delivery of hydrophobic drugs, including PTL. In this review, we summarized the key anticancer mechanisms underlined by PTL as well as engineered PTL nanoparticles synthesized to date. Therefore, PTL nanoformulations could be an alternative strategy to maximize the therapeutic value of PTL. Dove 2022-04-29 /pmc/articles/PMC9063801/ /pubmed/35517982 http://dx.doi.org/10.2147/DDDT.S355059 Text en © 2022 An et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
An, Tao
Yin, Huanhuan
Lu, Yanting
Liu, Feng
The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
title The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
title_full The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
title_fullStr The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
title_full_unstemmed The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
title_short The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
title_sort emerging potential of parthenolide nanoformulations in tumor therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063801/
https://www.ncbi.nlm.nih.gov/pubmed/35517982
http://dx.doi.org/10.2147/DDDT.S355059
work_keys_str_mv AT antao theemergingpotentialofparthenolidenanoformulationsintumortherapy
AT yinhuanhuan theemergingpotentialofparthenolidenanoformulationsintumortherapy
AT luyanting theemergingpotentialofparthenolidenanoformulationsintumortherapy
AT liufeng theemergingpotentialofparthenolidenanoformulationsintumortherapy
AT antao emergingpotentialofparthenolidenanoformulationsintumortherapy
AT yinhuanhuan emergingpotentialofparthenolidenanoformulationsintumortherapy
AT luyanting emergingpotentialofparthenolidenanoformulationsintumortherapy
AT liufeng emergingpotentialofparthenolidenanoformulationsintumortherapy